Mitsubishi UFJ Asset Management Portfolio holdings
AUM
$125B
1-Year Return
23.89%
This Quarter Return
+4.3%
1 Year Return
+23.89%
3 Year Return
+93.04%
5 Year Return
+163.06%
10 Year Return
+400.91%
AUM
$82B
AUM Growth
+$9.65B
(+13%)
Cap. Flow
+$7.68B
Cap. Flow
% of AUM
9.36%
Top 10 Holdings %
Top 10 Hldgs %
31.42%
Holding
1,609
New
45
Increased
827
Reduced
158
Closed
37
Top Buys
| 1 |
Microsoft
MSFT
|
+$473M |
| 2 |
NVIDIA
NVDA
|
+$453M |
| 3 |
Apple
AAPL
|
+$433M |
| 4 |
Constellation Brands
STZ
|
+$379M |
| 5 |
Amazon
AMZN
|
+$281M |
Top Sells
| 1 |
Philip Morris
PM
|
+$343M |
| 2 |
Amphenol
APH
|
+$256M |
| 3 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$74.4M |
| 4 |
Veralto
VLTO
|
+$69.5M |
| 5 |
iShares MBS ETF
MBB
|
+$34M |
Sector Composition
| 1 | Technology | 31.95% |
| 2 | Healthcare | 14.3% |
| 3 | Financials | 13.12% |
| 4 | Consumer Discretionary | 8.56% |
| 5 | Communication Services | 8.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
GOOD
901
Gladstone Commercial Corp
GOOD
$601M
| $360K | ﹤0.01% |
25,210
| – | – |
|
902
Smith & Nephew
SNN
$16.7B
| $358K | ﹤0.01% |
14,433
+1,994
| +16% | +$49.4K |
|
903
CONMED
CNMD
$1.65B
| $348K | ﹤0.01% |
5,013
+2,060
| +70% | +$143K |
|
|
FPI
904
Farmland Partners
FPI
$476M
| $346K | ﹤0.01% |
30,029
| – | – |
|
905
Chemours
CC
$2.51B
| $342K | ﹤0.01% |
15,161
-2,342
| -13% | -$52.9K |
|
|
GMRE
906
Global Medical REIT
GMRE
$514M
| $342K | ﹤0.01% |
37,656
| – | – |
|
907
Worthington Enterprises
WOR
$3.25B
| $334K | ﹤0.01% |
7,058
-1,726
| -20% | -$81.7K |
|
908
Gibraltar Industries
ROCK
$1.82B
| $328K | ﹤0.01% |
4,783
+4,706
| +6,112% | +$323K |
|
909
Lincoln Electric
LECO
$13.5B
| $322K | ﹤0.01% |
1,706
+27
| +2% | +$5.09K |
|
910
ICICI Bank
IBN
$113B
| $318K | ﹤0.01% |
11,050
+1,250
| +13% | +$36K |
|
911
Krystal Biotech
KRYS
$3.98B
| $317K | ﹤0.01% |
1,726
-517
| -23% | -$94.9K |
|
912
Fluence Energy
FLNC
$903M
| $316K | ﹤0.01% |
+18,231
| New | +$316K |
|
|
BFS
913
Saul Centers
BFS
$778M
| $311K | ﹤0.01% |
8,452
| – | – |
|
914
Genie Energy
GNE
$408M
| $310K | ﹤0.01% |
+21,212
| New | +$310K |
|
915
Grifois
GRFS
$6.86B
| $307K | ﹤0.01% |
48,642
+15,407
| +46% | +$97.1K |
|
916
Arrowhead Research
ARWR
$3.98B
| $305K | ﹤0.01% |
11,718
+3,377
| +40% | +$87.8K |
|
|
UHT
917
Universal Health Realty Income Trust
UHT
$572M
| $302K | ﹤0.01% |
7,711
| – | – |
|
918
CureVac
CVAC
$1.22B
| $298K | ﹤0.01% |
87,514
+45,324
| +107% | +$154K |
|
919
CVRx
CVRX
$210M
| $297K | ﹤0.01% |
24,809
+20,460
| +470% | +$245K |
|
920
Ultragenyx Pharmaceutical
RARE
$2.99B
| $295K | ﹤0.01% |
7,174
+1,123
| +19% | +$46.2K |
|
921
HDFC Bank
HDB
$181B
| $294K | ﹤0.01% |
4,571
| – | – |
|
922
Ionis Pharmaceuticals
IONS
$10B
| $289K | ﹤0.01% |
6,074
+2,232
| +58% | +$106K |
|
923
CRISPR Therapeutics
CRSP
$5.01B
| $288K | ﹤0.01% |
5,334
+2,002
| +60% | +$108K |
|
924
Rocket Pharmaceuticals
RCKT
$351M
| $282K | ﹤0.01% |
13,118
+2,217
| +20% | +$47.7K |
|
925
Arbutus Biopharma
ABUS
$958M
| $277K | ﹤0.01% |
+89,695
| New | +$277K |
|